Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 88Neoplasms 11Neoplasm Metastasis 10Glioma 8Ovarian Neoplasms 6Melanoma 6Glioblastoma 6Squamous Cell Carcinoma of Head and Neck 5Liposarcoma 5Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Recurrence 4Medulloblastoma 4Endometrial Neoplasms 4Diffuse Intrinsic Pontine Glioma 4Colorectal Neoplasms 4Brain Neoplasms 4Neuroblastoma 3Neoplasms by Site 3Lymphoma 3Hereditary Sensory and Autonomic Neuropathies 3Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Diseases 3Astrocytoma 3Triple Negative Breast Neoplasms 2Rhabdoid Tumor 2Prostatic Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Multiple Endocrine Neoplasia Type 1 2

Interventions

lutetium Lu 177 dotatate 34Everolimus 33lanreotide 13gallium Ga 68 dotatate 13Temozolomide 13Magnetic Resonance Spectroscopy 13Nivolumab 12pembrolizumab 11Octreotide 11Capecitabine 11177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9surufatinib 8Sunitinib 8Specimen Handling 7Carboplatin 7pasireotide 6amino-acid, glucose, and electrolyte solution 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Lutetium-177 5Ipilimumab 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5Bevacizumab 5telotristat ethyl 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuroendocrine Tumors × ribociclib × Clear all
NCT03070301 2024-10-10

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
21 enrolled 8 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡